FDA Brief

Warning letters Drugs

FDA warning letter to

Julio R. Flamini, M.D./Clinical Integrative Research Center of Atlanta

High riskIssued Aug 20, 2024Posted Sep 3, 2024Center for Drug Evaluation and Research (CDER)

FDA warns an Atlanta clinical investigator after a 15-year-old trial subject was given about 10 times the protocol dose.

What happened

FDA inspected Dr. Julio R. Flamini's clinical site in Atlanta from February 28 to March 11, 2024, reviewing his conduct of two clinical trials of investigational drugs. FDA found that at a May 15, 2023 study visit, a 15-year-old female subject who weighed 59.1 kg should have received about 1.2 mL (~12 mg) per day under the weight-based dosing plan, but was dispensed instructions for 12.0 mL per day and received 120 mg per day for seven days. FDA also said the site's March 25, 2024 written response did not give enough detail about the corrective actions to show they would prevent a repeat.

What FDA found

  1. The investigator did not follow the study's dosing plan: a 15-year-old subject got about 10 times the maximum daily dose for seven days, raising the risk of serious side effects.

    21 CFR 312.60
  2. The written corrective action plan did not include enough detail on the procedures put in place to prevent the same dosing error from happening again.

What FDA wants

Within 15 business days of receiving the letter, the site must write to FDA describing the actions taken to prevent similar violations, including follow-up details on the dosing procedures now in place. If the site believes it complied with the law and regulations, it should send its reasoning and supporting information.

Who should pay attention

  • clinical trial sites and investigators running drug studies
  • sponsors and contract research organizations monitoring investigator sites
  • sites that rely on electronic dose calculators or sponsor dispensing software

This is a summary. Read the original letter on fda.gov.